Replies to post #217345 on Biotech Values

[biotech jim]

IFRX

This is what Leerink had to say about the Ph2B HS trial:

The Ph.IIb trial will be a randomized, double-blind,
placebo-controlled, multicenter global study (~50 trial sites), which is
expected to enroll ~175 patients (n=35/ cohort) with the aim of assessing
the safety/ tolerability and efficacy of IFX-1 in HS patients as measured
by the Hidradenitis Suppurativa Clinical Response (HiSCR) after 16 wks.
of treatment.

Unfortunately, I have nothing to add regarding trial design or comparitor(s),